Peter Clark, PhD is the Head of Computational Drug Design at Novo Nordisk, where he leads a global, interdisciplinary team of computational scientists focused on accelerating the delivery of differentiated therapeutics to patients through applied digital innovation across the R&D value chain. His scientific expertise and executive leadership in the field have led to the delivery of several clinical candidates and approved therapies including CAR-T, gene therapy, peptides, biologics (antibodies) and small molecules assets. Prior to joining Novo Nordisk, Peter served as the Global Head of Computational Science & Engineering within the Therapeutics Discovery (TD) organization of Johnson & Johnson Innovative Medicines, and also served as the Director of Bioinformatics at the University of Pennsylvania, Perelman School of Medicine, where he worked closely with academic and commercial collaborators on the design, optimization and technology transfer of gene therapy assets from early research and development through commercially partnered IND enabling clinical studies. Peter’s diverse expertise in computer science, engineering, clinical molecular genetics, computational biology, and translational research has led to the publication of over 60 peer-reviewed scientific publications as well as three book chapters, several issued patents and three biotechnology spin-off companies.